Company intelligence / Profile preview

Xadcera Biopharmaceutical

Ownership: Private
Development stage: Other

Overview

Xadcera has two bispecific ADC programs in Phase 1 clinical trials as of early 2025. Both DM001 and DM002 received FDA IND approval in 2024 and are being tested internationally, including the US and Australia. The company is focused on dual-targeting ADCs for solid tumors with global rights to its lead assets[2][4].

Therapeutic areas: Oncology
Modalities: Antibody drug conjugate (ADC)Bispecific monoclonal antibody
Industry: Biotech

Partnerships

Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Beyond the preview

Go deeper on Xadcera Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xadcera Biopharmaceutical.

Explore the full profile